close

Parexel International Corporation, a biopharmaceutical services company, provides clinical research, medical communications services, consulting and informatics, and technology products and services to the pharmaceutical, biotechnology, and medical device industries worldwide. It operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics, Inc. (Perceptive). The CRS segment provides clinical trials management and biostatistics, data management, and clinical pharmacology, as well as related medical advisory and investigator site services. It manages various aspects of clinical trials, including study and protocol design, case report form design, site and investigator recruitment, patient enrollment, study monitoring and data collection, data analysis, report writing, and medical services. This segment provides services in various therapeutic areas, including cardiology, oncology, infectious diseases, neurology, allergy/immunology, endocrinology/metabolism, gastroenterology, obstetrics/gynecology, orthopedics, pediatrics, psychiatry, and transplantation. The PCMS segment offers technical advice in areas, such as drug development, regulatory affairs, and biopharmaceutical process and management consulting. It also provides market development, product development, and targeted communications services in support of product launch. In addition, its consultants identify alternatives and propose solutions to address clientsÂ’ product development, registration, and commercialization issues, as well as offers health policy consulting and reimbursement services. The Perceptive segment provides information technology solutions comprising medical imaging services, IVRS, CTMS, Web-based portals, systems integration, and patient diary applications. The company was founded in 1983 and is headquartered in Waltham, Massachusetts.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	26.16
Volume	548744
Volume Avg	412868
52 Week High	27.91
52 Week Low	15.26
PE	43.03
PE (group average)	39
EPS Year	0.60
EPS change Q/Q	-6.9%
EPS change Q/Q Yr ago	22.73%
EPS change Q/Q next Q est	-28.95%
EPS change Y/Y	-43.52%
REV change Q/Q	-3.02%
REV change Q/Q Yr ago	2.5%
EPS next Q est	0.38
EPS next Y est	1.52
Divident Annual	0.00
Dividend Yield	0%